NEW & EXPANDED COVERAGE FOR 2017
Cancer Biotherapeutics is now part of Immuno-Oncology Summit Europe, taking place 20-24 March 2017 in London. View details at Immuno-OncologyEurope.com
2016 FEATURED PRESENTERS
 Sergio A. Quezada, Ph.D.
Professorial Research Fellow, Research Haematology, University College London Cancer Institute
|
 Martin Pule, Ph.D.
Senior Lecturer,
Haematology,
UCL Cancer Institute
|
 Dario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich
|
 Stefan Dübel, Ph.D.
Managing Director and Professor, Biotechnology, Technische Universität Braunschweig
|
 John McCafferty, Ph.D.
CEO, IONTAS
|
|
ABOUT THE EVENT
Research in Cancer Biotherapeutics is progressing in leaps and bounds with rapid and exciting developments taking place with many different approaches. Cambridge Healthtech Institute, the producer of PepTalk and PEGS Protein & Antibody Engineering Summits, are responding by introducing a European event concentrating solely on this topic. Coverage focuses strongly on immunotherapy, with case studies on immune check point inhibitors, agonistic and immunomodulatory approaches, immunocytokines, chimeric antigen receptors, retargeting T cells, immunomodulatory bispecifics, oncolytic immunotherapy, and the role of dendritic cells. We also broaden the scope with presentations on targets and lead selection, fusion proteins, ADCs, and on recreating the tumour microenvironment for translational studies.
ATTENDEE TESTIMONIALS
“It was a really nice conference, in terms of the topics, the choice of speakers and the size of the meeting which lent itself well to having informal discussions during the breaks.”
Chief Science Officer, Innate Pharma
“A very informative meeting with a focus on immunotherapy, one of the most interesting fields in oncology currently. The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented.”
Principal Scientist, Medicinal Chemistry, Pfizer, Inc.
View Additional Attendee Quotes
